BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
BriaCell and its majority-owned subsidiary BriaPro presented four posters of positive preclinical immunotherapy data at the SITC 41st Annual Meeting in Phoenix, Nov. 4-8, 2026. Key findings include broad immune activation and sustained cancer-cell killing from the Bria-OTS+ platform, BP-80 tolerability in a four-week GLP nonhuman primate study with a NOEL of 50 mg/kg/dose, and engineered CD80 constructs showing 49-fold and 130-fold-plus improved PD-L1 binding affinity.
Key figures
- Bp80 noel
- 50 mg/kg/dose
- Cd80 fc pd-l1 affinity improvement
- more than 130-fold stronger PD-L1 binding
- Tilsrx001 pd-l1 affinity improvement
- 49-fold higher PD-L1 binding affinity
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.